Survival Outcomes in Tyrosine Kinase Inhibitor Refractory Patients in Chronic Phase CML: A Single Center Retrospective Analysis
Little is known regarding the long term outcomes of CML patients who fail to achieve early complete cytogenetic remission (CCyR) with tyrosine kinase inhibitors (TKIs) in terms of disease progression and survival.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Justin Shaya, Phillip Boonstra, Malathi Kandarpa, Moshe Talpaz Source Type: research